Fig 1.
The mRNA expression of eIF4G1 in ovarian cancer tissues and normal ovary epithelial cell specimens.
(A) Real-time RT PCR analysis of eIF4G1 in fresh frozen ovarian cancer samples and normal ovarian surface epithelial cell specimens in our study (P = 0.0375). (NORMAL:27 normal ovarian surface epithelial cell specimens;CANCER:40 frozen ovarian cancer samples). (B) Relative eIF4G1 mRNA expression of ovarian cancer samples and normal ovarian surface epithelial cells from the reported microarray data (accession number GSE18521) (P<0.0001; NORMAL: 10 normal ovarian tissues; CANCER: 53 snap-frozen ovarian cancer tissue specimens). (C) Relative eIF4G1 mRNA expression of ovarian cancer samples and normal ovarian surface epithelial cells from reported microarray data (accession number GSE40595; P = 0.0028; NORMAL: 6 normal ovarian surface epithelial cells; CANCER: 35 snap-frozen ovarian cancer tissue specimens). Scatter plot represents means ± SD.
Fig 2.
The expression of eIF4G1 at the protein level in ovarian cancer tissues from patients.
(Left, ×40; Right, ×100) Immunohistochemical staining of eIF4G1 in ovarian cancer tissue at different staining score using anti-human eIF4G1 antibodies. (Left magnification, ×40; Right magnification, ×100).
Fig 3.
Summary of relative eIF4G1 protein expression in normal and ovarian cancer specimens assessed by IHC.
Intensity of eIF4G1 staining was scored from 1 to 4, and an individual box plot was generated to display the distribution of the intensity of eIF4G1 staining for normal ovary samples and ovarian cancer specimens. Immunohistochemical analysis of eIF4G1 in FFPE ovarian cancer samples (n = 134) and normal FFPE ovarian surface epithelial specimens (n = 18). P = 0.0007. (NORMAL: normal FFPE ovarian surface epithelial specimens; CANCER: FFPE ovarian cancer samples).
Table 1.
Baseline Characteristics of the 134 Patients of Serous Ovarian Cancer.
Fig 4.
Correlation of eIF4G1 protein expression with clinicopathological stage of ovarian cancer tissues used for eIF4G1 expression analysis.
Immunohistochemical analysis of eIF4G1 with stage I and II of ovarian cancer samples (n = 31) and stage III and IV of ovarian cancer samples (n = 102). P = 0.004.
Fig 5.
Correlation of eIF4G1 protein expression with the presence of omentum metastasis of ovarian cancer tissues used for eIF4G1 expression analysis.
Immunohistochemical analysis of eIF4G1 without omentum metastasis of ovarian cancer samples (n = 46) and with omentum metastasis of ovarian cancer samples (n = 86). P = 0.024.
Table 2.
Associations of cancerous eIF4G1 expression with clinicopathologic characteristics of ovarian cancer.
Table 3.
Prognostic factors of Ovarian Cancer after resection (PFS).
Table 4.
Prognostic factors of Ovarian Cancer after resection (OS).
Fig 6.
Post-surgical overall survival correlates with eIF4G1 protein expression in ovarian cancer.
(A) Overall survival rates for cases with high eIF4G1 expression versus cases with low eIF4G1 expression levels in ovarian cancer patients. (B) Post-surgical progression free survival rates for cases with high eIF4G1 expression versus cases with low eIF4G1 expression levels in ovarian cancer patients. There were 40 patients with low eIF4G1 expression and 93 patients with high eIF4G1 expression. However, due to missing survival data, only 72 and 79 patients with high eIF4G1 as well as 28 and 31 patients with low eIF4G1 expression were included for progression-free survival analysis and overall survival analysis, respectively.